PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Annals of Oncology10.1093/annonc/mdz422.037201930ix55Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinomaJ. Ha, K. Bang, C. Yoo, J. Jeong, H.-M. Chang, D. Oh, T.J. Song, D.H. Park, S.S. Lee, S.K. Lee, M.-H. Kim, J.-H. Park, K.-P. Kim, B.-Y. Ryoohttps://api.elsevier.com/content/article/PII:S092375341957836X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S092375341957836X?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/30/Supplement_9/mdz422.037/31094346/mdz422.037.pdf, http://academic.oup.com/annonc/article-pdf/30/Supplement_9/mdz422.037/31094346/mdz422.037.pdf
Gastroenterology10.1016/s0016-5085(20)32006-020201586S-527Su1157 EFFICACY OF MODIFIED FOLFIRINOX AS SECOND-LINE CHEMOTHERAPY IN METASTATIC PANCREATIC ADENOCARCINOMA AFTER GEMCITABINE PLUS NAB-PACLITAXEL FAILUREKenji Ikezawa, Ryosuke Kiyota, Ryoji Takada, Toshihiro Imai, Abe Yutaro, Nobuyasu Fukutake, Nawa Takatoshi, Kazuhiro Katayama, Kazuyoshi Ohkawahttps://api.elsevier.com/content/article/PII:S0016508520320060?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508520320060?httpAccept=text/plain
Cancer Research and Treatment10.4143/crt.2019.1902020521254-262Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic AdenocarcinomaKyoungmin Lee, Kyunghye Bang, Changhoon Yoo, Inhwan Hwang, Jae Ho Jeong, Heung-Moon Chang, Dongwook Oh, Tae Jun Song, Do Hyun Park, Sang Soo Lee, Sung Koo Lee, Myung-Hwan Kim, Jin-hong Park, Kyu-pyo Kim, Baek-Yeol Ryoohttp://e-crt.org/upload/pdf/crt-2019-190.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2019.190, http://e-crt.org/upload/pdf/crt-2019-190.pdf
Japanese Journal of Clinical Oncology10.1093/jjco/hyac1452022Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancerTakafumi Mie, Takashi Sasaki, Takeshi Okamoto, Tsuyoshi Takeda, Chinatsu Mori, Takaaki Furukawa, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahirahttps://academic.oup.com/jjco/advance-article-pdf/doi/10.1093/jjco/hyac145/45878647/hyac145.pdf, https://academic.oup.com/jjco/advance-article-pdf/doi/10.1093/jjco/hyac145/45878647/hyac145.pdf
Journal of Cancer Research and Clinical Oncology10.1007/s00432-020-03442-0202014751529-1536Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized studyYuan Zong, Jiajia Yuan, Zhi Peng, Ming Lu, Xicheng Wang, Lin Shen, Jun Zhouhttp://link.springer.com/content/pdf/10.1007/s00432-020-03442-0.pdf, http://link.springer.com/article/10.1007/s00432-020-03442-0/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00432-020-03442-0.pdf
Value in Health10.1016/j.jval.2016.03.20052016193A141Incidence Of Neutropenia In Patients Receiving Either Nab-Paclitaxel Plus Gemcitabine Or Folfirinox As First-Line Treatment For Metastatic Pancreatic AdenocarcinomaM Parisi, M Patel, K Belk, CW Craverhttps://api.elsevier.com/content/article/PII:S1098301516302935?httpAccept=text/plain, https://api.elsevier.com/content/article/PII:S1098301516302935?httpAccept=text/xml
Cancer Management and Research10.2147/cmar.s2637732020Volume 1212657-12666<p>Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma</p>Yuan Zong, Zhi Peng, Xicheng Wang, Ming Lu, Lin Shen, Jun Zhouhttps://www.dovepress.com/getfile.php?fileID=64628, https://www.dovepress.com/getfile.php?fileID=64628
Cancer Management and Research10.2147/cmar.s2673932020Volume 1210271-10278<p>FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer</p>Martina Catalano, Raffaele Conca, Roberto Petrioli, Monica Ramello, Giandomenico Roviellohttps://test.dovepress.com/getfile.php?fileID=62660, https://test.dovepress.com/getfile.php?fileID=62660
Annals of Oncology10.1093/annonc/mdz155.303201930iv83-iv84Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with performance status two or lessA. Das, A. Deanhttps://api.elsevier.com/content/article/PII:S0923753419308191?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419308191?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/30/Supplement_4/mdz155.303/28892374/mdz155.303.pdf
Chemotherapy10.1159/000517244202166358-64Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective AnalysisKotone Hayuka, Hiroyuki Okuyama, Akitsu Murakami, Yoshihiro Okita, Takamasa Nishiuchi, Keiichi Okano, Yasuyuki Suzuki, Akihito Tsujihttps://www.karger.com/Article/Pdf/517244, https://www.karger.com/Article/Pdf/517244